Just Published: "Ghana Pharmaceuticals & Healthcare Report Q2 2015"

Our outlook for Ghana's pharmaceutical and healthcare market is becoming increasingly bearish. The National Health Insurance Scheme is facing backlash from both drugmakers and service providers due to a lack of payments. Furthermore, we believe that the scheme will come under even more scrutiny in light of the proposed government spending revision on the back of lower oil prices.

Headline Expenditure Projections

Pharmaceuticals: GHS1.01bn (USD329mn) in 2014 to GHS1.18bn (USD316mn) in 2015; +16.5% in local currency terms and -4.1% in US dollar terms. Forecast in line with Q115 in local currency terms and slightly downwards in US dollar terms due to currency depreciation.

Healthcare: GHS5.06bn (USD1.65bn) in 2014 to GHS5.85bn (USD1.57bn) in 2015; +15.5% in local currency terms and -5.0% in US dollar terms. Forecast in line with Q115 in local currency terms and slightly downwards in US dollar terms.

Risk/Reward Index

In BMI's Q215 MEA regional Pharmaceuticals & Healthcare RRI, Ghana scores 37.9 points out of 100, below the regional average of 42.5. Ghana has moved up to 20th out of a total of 31 countries, up from 27nd in Q115, posting a better performance in terms of Risks than Rewards. BMI notes that the depreciating Ghanaian cedi is having a negative impact on short term pharmaceutical market growth, which is a key contributor the country's low score this quarter.

Full Report Details at
- http://www.fastmr.com/prod/980238_ghana_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Key Trends And Developments

* The US Food and Drug Administration (FDA) inaugurated an inter-agency task force in Accra in March 2015, to monitor, seize and share information on substandard and counterfeit medical products. The task force will report to the World Health Organization (WHO) and other regulators, and share intelligence on product enforcement, surveillance, quality and suspicious market activity.
* It was reported in March 2015, due to the non-payment of National Health Insurance Scheme (NHIS) claims, the operations of Central Regional Medical Stores and health service delivery...

The Ghana Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Ghana Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Ghana pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Ghana, to test other views - a key input for successful budgeting and strategic business planning in the Ghanaian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- United Arab Emirates Pharmaceuticals & Healthcare Report Q2 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Italy Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015